C

Caris

Provides AI-powered molecular insights for cancer

International Marketing Manager

Full-TimeUpdated on 10/23/2026
$108k - $120k/yr+ Target incentive, if applicable
Senior
Bachelor's, MBA, PhD
Phoenix, AZ, USA+1 moreMore locations: Irving, TX, USA
HybridHybrid onsite 3–4 days per week in Irving, Texas or Phoenix, Arizona; periodic travel, potentially international.
Growth & MarketingMarketing Generalist & Management

About the job

Requirements
  • A bachelor's degree from an accredited university or college in marketing, communications, or a scientific field is required.
  • At least 5 years of experience in marketing, communications, or product management is required.
  • Prior healthcare experience in areas such as in vitro diagnostics, medical devices, or pharmaceuticals is required.
  • A firm understanding of marketing principles and demonstrated experience managing marketing projects from beginning to end are required.
  • Experience with conference and event management and vendor management is required.
  • Proficiency in Microsoft Office Suite, specifically Word, Excel, and Outlook, is required, as is exposure to content management systems and project management software and general working knowledge of the Internet for business use.
  • The position requires onsite presence 3–4 days per week, with the remaining days worked remotely.
  • The ability to lift objects over 20 pounds and to sit and/or stand for long periods is required.
Responsibilities
  • Support international commercial and operational teams while based in Dallas, Texas or Phoenix, Arizona, with flexible hours to accommodate time zone differences.
  • Manage multiple projects simultaneously, meeting deadlines while maintaining high quality and alignment with corporate strategy and compliance standards.
  • Contribute to developing and executing country-specific marketing plans, support product launches, and manage growth initiatives aligned with regional sales objectives and global marketing priorities.
  • Support creation, adaptation, and translation of product portfolio content, and manage the content lifecycle by region.
  • Manage international conferences and events, maintaining consistent brand identity and messaging while adapting them for market needs.
  • Prepare and equip distributor teams with enablement tools, including playbooks, training materials and guides, promotional content, transactional content such as requisitions and patient consents, and event materials.
  • Support distributor onboarding, training and education, and ad hoc requests across time zones.
  • Maintain an accurate, up-to-date international marketing campaign calendar and support tracking marketing project timelines, resources, and effectiveness through key performance indicators.
  • Manage Medical, Legal, and Regulatory submissions; establish content-dissemination best practices and ensure content accuracy.
  • Manage special projects as assigned.
  • Work with product marketing managers, graphic designers, sales, regulatory and compliance, legal, and partners to build region-focused strategies that support growth objectives.
  • Build and maintain relationships with key international stakeholders, communicating feedback and regional insights to drive improvements.
  • Travel periodically, including potential international travel, and attend some evenings, weekends, or holidays to meet project deadlines or support medical association conferences.
  • Attend periodically scheduled after-hours meetings and/or provide response support outside normal working hours.
Desired Qualifications
  • An advanced degree (MBA or PhD) is preferred.
  • International marketing or business experience and molecular science or precision medicine experience are preferred.
  • Experience with campaign orchestration and execution is preferred.
  • Project management and cross-functional leadership skills are preferred.
  • Familiarity with Salesforce and marketing automation software is preferred.
  • A valid passport or the ability to obtain one within six months of hire is preferred.

About the company

Caris Life Sciences provides molecular information to cancer patients, oncologists, researchers, and payors to guide personalized cancer care. Its core product uses molecular profiling and artificial intelligence to interpret a cancer’s molecular features at diagnosis, helping predict how the cancer may behave and which treatments are likely to work. The company differentiates itself by delivering a comprehensive, AI-assisted set of molecular insights across multiple stakeholders, translating complex genomic and other molecular data into actionable treatment guidance. Its goal is to improve cancer outcomes by enabling more precise, tailored therapy for each patient.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Irving, Texas

Founded

1996

Get referred to Caris

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 45% to $263.7 million, with 68% gross margin.
  • August 5, 2026 guidance increased to $1.03 billion-$1.04 billion after positive free cash flow.
  • September 2026 campaigns and Everlywell commercialization expand Caris Detect awareness and distribution.

What critics are saying

  • DOJ’s March 2025 False Claims Act CID over Medicare 14-day rule remains unresolved.
  • Caris Detect faces Guardant and Grail competition; physicians can standardize on incumbents fast.
  • If Detect adoption stalls in 2027, Caris remains a single-platform lab and valuation compresses.

What makes Caris unique

  • Caris built 1.13 million profiles and 845,000 matched profiles by June 30, 2026.
  • Caris Detect pairs whole-genome, whole-transcriptome sequencing with AI and 50 billion markers.
  • Caris ChromoSeq and MI Clarity extend one platform across heme and breast oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Health Savings Account/Flexible Spending Account
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • 401(k) Company Match
  • Employee Assistance Program
  • Pet Insurance
  • Legal Assistance
  • Tuition Assistance

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Oct 14th, 2026
Caris Life Sciences to present eight Studies highlighting the power of AI, multi-omics and precision medicine at ESMO 2026.

Caris Life Sciences to present eight Studies highlighting the power of AI, multi-omics and precision medicine at ESMO 2026. Oct 14, 2026, 08:30 ET Eight posters will feature AI-driven approaches to treatment prediction, risk stratification and biomarker discovery advancing precision medicine across multiple cancer types IRVING, Texas, Oct. 14, 2026 /PRNewswire/ - Caris Life Sciences(R)(NASDAQ: CAI), a leading TechBio company, today announced that researchers from Caris and the Caris Precision Oncology Alliance(R)(Caris POA) will present eight posters at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. The research showcases the expanding impact of artificial intelligence, molecular profiling and multimodal data integration in advancing precision oncology across multiple tumor types. The two Caris-led posters focus on AI-driven treatment prediction and risk stratification in breast cancer, as well as six collaborative investigations conducted with members of the Caris POA. Together, the posters span breast, lung, endometrial, melanoma and immuno-oncology research and demonstrate how comprehensive molecular and clinico-genomic data can reveal novel biological insights and inform more personalized treatment approaches. "Artificial intelligence is transforming our ability to understand cancer biology and predict therapeutic response on an unprecedented scale," said James Hamrick MD, MPH, Chairman of the Caris POA. "The posters to be presented at ESMO 2026 highlight how the integration of AI, molecular profiling and real-world clinical data can uncover clinically meaningful insights that ultimately help guide more precise treatment decisions for patients." Caris-Led Studies Posters: 178P - Caris CapeAI, An Artificial Intelligence Model of ER+ Breast Cancer Response to Capecitabine Authors: Javier Pascual Lopez, Chen Sun, Miguel J. Gil, et al. Session: AI for clinical workflows and decision-making Date and time: Sunday, 25 October 2026, 12:00-12:45 (Madrid time) 217P - Toward Precision Extended Endocrine Therapy in Early HR+ Breast Cancer: Multimodal AI for Risk and Benefit Stratification Authors: Eleftherios P. Mamounas, Md Ashequr Rahman, Ming Chen, et al. Session: AI for clinical workflows and decision-making Date and time: Sunday, 25 October 2026, 12:00-12:45 (Madrid time) Caris Precision Oncology Alliance Collaborative Studies Posters: 3285P - Characterization of G-protein coupled estrogen receptor (GPER) and estrogen receptor in EGFR-mutated NSCLC leading to survival differences Authors: Robert Hsu, Mercy Kehinde-Ige, Sharon Wu, et al. Session: Pathology and molecular pathology Date and time: Friday, 23 October 2026, 15:15-16:00 (Madrid time) 1296P - Genomic Scar-Defined Homologous Recombination Deficiency (HRD) and Tumor Immune Microenvironment in Endometrial Cancer (EC) Authors: Hiromichi Nakajima, Kenichi Harano, Sharon Wu, et al. Session: Gynecological cancers Date and time: Monday, 26 October 2026, 12:00-12:45 (Madrid time) 4395P - A 25-gene T-cell exhaustion signature refines TLS-based prediction of immunotherapy benefit Authors: Nathan El Ghazzi, Andrew Elliott, George Sledge, et al. Session: Translational research and biomarkers Date and time: Friday, 23 October 2026, 15:15-16:00 (Madrid time) 2136P - Site-dependent stromal-mesenchymal reprogramming associated with survival and immunotherapy outcomes in BAP1-mutant uveal melanoma (UM) Authors: Clara J. Oh, Jingshu Chen, Nishant Gandhi, et al. Session: Melanoma Date and time: Saturday, 24 October 2026, 12:00-12:45 (Madrid time) 2681P - Characterization of differences across Organ Site Specific Metastasis in NSCLC by Race/Ethnicity Authors: Robert Hsu, Nishant Gandhi, Krithika Chennapan, et al. Session: NSCLC, metastatic Date and time: Monday, 26 October 2026, 12:00-12:45 (Madrid time) 2686P - RRAS2mt Non-small cell lung cancer (NSCLC) defines a distinct subset of RASmt NSCLC Authors: Sharon Wu, Hui Jing Hoe, Eleonora Gariazzo, et al. Session: NSCLC, metastatic Date and time: Monday, 26 October 2026, 12:00-12:45 (Madrid time) Research highlights will be available at the Caris booth #1021. About the Caris Precision Oncology Alliance The Caris Precision Oncology Alliance(R)(Caris POA) is a global collaborative network of leading cancer centers, academic institutions, research consortia and healthcare organizations dedicated to advancing precision oncology and biomarker-driven research. Through collaboration and innovative scientific programs, the Caris POA works to improve patient care and further the development of precision medicine. About Caris Life Sciences Caris Life Sciences(R)(Caris) is a leading TechBio company actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. Forward Looking Statements This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases, forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," or "continue" or similar expressions. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: continued development, performance and commercialization of Caris Detect; developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; the impact on our future volumes of the continued execution of our strategy to re-align and expand our sales organization; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions, including our application for New York State Department of Health approval for Caris Assure; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties; and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. Caris Life Sciences Media: Corporate Communications [email protected] 214.294.5606 SOURCE Caris Life Sciences

Investor's Business Daily
Oct 2nd, 2026
Caris Life Sciences stock more than doubles in two months after raising guidance to $1B

Caris Life Sciences, which went public on 18 June 2025 at $21 per share, has more than doubled in value in less than two months. The biotech company uses artificial intelligence to profile genetic material, helping clients develop medicines for cancer and other diseases. On 5 August, Caris reported break-even second-quarter results, compared to a loss of $7.97 per share the previous year. Revenue jumped 45% to $263.7 million, with molecular profiling services growing 55% to $252.3 million. Management raised full-year 2026 revenue guidance to between $1.03 billion and $1.04 billion, representing potential growth of 27% to 28%. Wall Street expects the company to turn a profit of 12 cents per share this year.

PR Newswire
Sep 29th, 2026
Caris Life Sciences launches enhanced Caris Assure liquid biopsy with integrated DNA, RNA and whole-blood analysis

Caris Life Sciences has launched an enhanced version of its Caris Assure liquid biopsy platform. The upgraded assay integrates Whole Exome Sequencing, Whole Transcriptome Sequencing, and whole-blood analysis into a single platform, providing a comprehensive molecular profile from one blood draw. The enhanced platform covers more than 23,000 genes with therapy-focused sequencing depth reaching up to 40,000x. It includes validated Human Leukocyte Antigen reporting and expanded pharmacogenomic reporting, with a median turnaround time of approximately seven days. The upgraded version can distinguish tumour-derived alterations from clonal haematopoiesis and includes validation that tumour fraction correlates with risk of progression and treatment efficacy. Results are categorised into molecular response, intermediate, or molecular progression for patients receiving repeated testing during treatment. The Irving, Texas-based AI TechBio company aims to provide physicians with deeper biological insights for precision oncology decisions.

TIKR
Aug 24th, 2026
Caris Life Sciences Stock is up 65% in Three Months, but its valuation multiple just got cheaper.

Caris Life Sciences Stock is up 65% in Three Months, but its valuation multiple just got cheaper. Last updated Aug 24, 2026 Key Takeaways for Caris Life Sciences Stock as of August 2026. * Three-Month Run: Caris Life Sciences stock has climbed 65% since late May, closing at $26.27 on August 21 after a 45% year-over-year Q2 revenue beat flipped the growth story into a profitability story. * Street Split: 9 buys, 1 outperform, 3 holds among 12 analysts. * Model Upside: TIKR's mid-case valuation model targets $100 by December 2030, implying a 281% total return, or 36% annualized, from today's price. * Target Lag: The Street's mean target fell from $39 in September 2025 to $27 today, so this rally closed the valuation gap mostly through price appreciation rather than analysts raising numbers. Why Caris Life Sciences Stock Jumped 65% in Three Months. Caris Life Sciences (CAI) stock has climbed 65% since late May, closing at $26.27 on August 21 after a second-quarter report that turned a cash-burn growth story into a profitable one. The company posted revenue of $263.7 million on August 5, up 45% year over year, and narrowed its net loss to $0.6 million from $71.8 million a year earlier. That swing did the heavy lifting. Adjusted EBITDA rose to $55.7 million from $16.7 million a year ago, and Caris Life Sciences raised its full-year revenue guidance to a range of $1.03 billion to $1.04 billion, up from a prior $1 billion to $1.02 billion. Clinical case volume hit a record 59,200, up 18% year over year, driven by a sales force that grew past 300 reps. Vice Chairman and EVP Brian Brille put the inflection plainly on the Q2 earnings call: "Notably, this is our fifth consecutive quarter of positive adjusted EBITDA and positive free cash flow, and it provides us with valuable strategic flexibility for ongoing investment in our platform, new products and new channels such as MCED." That streak is what separated this print from prior quarters where growth came bundled with widening losses. Wall Street split on how far to take that story. BTIG lifted its target to $33 and Evercore ISI moved to $26 within two days of the report, while JPMorgan cut its target to $25 from $30 the same week. Caris Life Sciences stock kept climbing anyway, adding a further 6.88% on August 21 alone to close at $26.27, with no fresh company announcement that day. Even after the rally, Caris Life Sciences stock's NTM price to normalized earnings multiple has actually compressed, from 99 times on June 30 to 92x on August 21, the same three-month stretch in which the stock climbed 65%. That multiple was negative a year earlier and spiked above 719x in December 2025, when forward earnings estimates were still near zero, before settling in the 90 to 120 range as those estimates turned durably positive. The 65% move traded almost entirely on rising earnings estimates, not on investors paying more for the same dollar of forward profit. The 65% run reflects a business the market now believes can fund its own growth, not a name still chasing the multiple it had in May. Caris Life Sciences stock's earnings turn is the reason for the move. What comes next depends on whether the Street or the model has the longer horizon right. Caris Life Sciences Stock's Target Gap Has Nearly Closed. Wall Street's current read on Caris Life Sciences stock splits 9 buys, 1 outperform, and 3 holds across 12 analysts, with a mean target of $27 sitting just 3% above the $26.27 close. That gap has not always been this tight. The mean target stood at $39 in September 2025, fell to $38 by year end, then to $28 by June 2026 as the stock itself cratered to $17.82. evAnalysts were cutting numbers through the first half of the year almost as fast as the stock was falling. What changed since is the price, not the target: the mean has actually edged down further, from $28 to $27, even as Caris Life Sciences stock rallied 65% off its lows. Coverage grew from 8 analysts a year ago to 12 today, and holds appeared for the first time this cycle, growing to 3. The August run closed the valuation gap almost entirely through price catching up to a target range the Street had already set months earlier. TIKR's $100 Target Prices In Caris Life Sciences Stock's MCED Ramp. TIKR's mid-case model values Caris Life Sciences stock at $100 by December 2030, implying a 281% total return from the current price of $26.27, or 36% annualized over the next 4.4 years. That annualized rate sits well above what a mature diagnostics name typically offers investors, reflecting a model still treating Caris Life Sciences as an early-stage compounder rather than a business trading on this quarter's earnings alone. The gap between TIKR's $100 target and the Street's $27 mean target comes down to time horizon. Sell-side targets rarely price a stock more than 12 months out, while TIKR's model extends through the ramp of Caris Detect, the 58-cancer multi-cancer early detection test that launched in June and that management already flags as running ahead of lab capacity. Should You Invest in Caris Life Sciences, Inc.? The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question. Pull up Caris Life Sciences, Inc. stock and you'll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down. You can build a free watchlist to track Caris Life Sciences, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself. Looking for New Opportunities? * See what stocks billionaire investors are buying so you can follow the smart money. * Analyze stocks in as little as 5 minutes with TIKR's all-in-one, easy-to-use platform. * The more rocks you overturn... the more opportunities you'll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR. Disclaimer: Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or its content team, nor are they recommendations to buy or sell any stocks. TIKR create its content based on TIKR Terminal's investment data and analysts' estimates. Its analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing! Table of Contents * Key Takeaways for Caris Life Sciences Stock as of August 2026 * Why Caris Life Sciences Stock Jumped 65% in Three Months * Caris Life Sciences Stock's Target Gap Has Nearly Closed * TIKR's $100 Target Prices In Caris Life Sciences Stock's MCED Ramp * Should You Invest in Caris Life Sciences, Inc.? * Looking for New Opportunities? * Disclaimer: General Investing Earnings Updates Join thousands of investors worldwide who use TIKR to supercharge their investment analysis.

PR Newswire
Aug 6th, 2026
AI model predicts late breast cancer recurrence risk from standard pathology images

Caris Life Sciences has published research demonstrating a multimodal AI approach to predict late distant recurrence risk in hormone receptor-positive early breast cancer. The study appeared in Cancer Research Communications. The research, conducted with ECOG-ACRIN and NRG Oncology, integrated digitised pathology images with clinical data to generate risk predictions. The model was developed using specimens from 2,271 patients and validated in an independent cohort of 4,300 patients from the TAILORx study. In validation, the model identified a 10-year absolute distant recurrence risk difference of nearly 8% between high- and low-risk groups. It independently predicted late recurrence risk even after accounting for established clinical factors and the Oncotype DX Recurrence Score. The AI-based approach could offer a more accessible alternative to existing genomic assays by leveraging routinely available pathology slides, potentially helping oncologists identify patients at elevated risk and inform extended endocrine therapy decisions.